Accurate Identification and Quantification of DNA Species by Next-Generation Sequencing in Adeno-Associated Viral Vectors Produced in Insect Cells
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viral (rAAV) vectors have proven excellent tools for the treatment of many genetic diseases and other complex diseases. However, the illegitimate encapsidation of DNA contaminants within viral particles constitutes a major safety concern for rAAV-based therapies. Moreover, the development of rAAV vectors for early-phase clinical trials has revealed the limited accuracy of the analytical tools used to characterize these new and complex drugs. Although most published data concerning residual DNA in rAAV preparations have been generated by quantitative PCR, we have developed a novel single-strand virus sequencing (SSV-Seq) method for quantification of DNA contaminants in AAV vectors produced in mammalian cells by next-generation sequencing (NGS). Here, we describe the adaptation of SSV-Seq for the accurate identification and quantification of DNA species in rAAV stocks produced in insect cells. We found that baculoviral DNA was the most abundant contaminant, representing less than 2.1% of NGS reads regardless of serotype (2, 8, or rh10). Sf9 producer cell DNA was detected at low frequency (≤0.03%) in rAAV lots. Advanced computational analyses revealed that (1) baculoviral sequences close to the inverted terminal repeats preferentially underwent illegitimate encapsidation, and (2) single-nucleotide variants were absent from the rAAV genome. The high-throughput sequencing protocol described here enables effective DNA quality control of rAAV vectors produced in insect cells, and is adapted to conform with regulatory agency safety requirements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform
Kircher, M., Sawyer, S., & Meyer, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr771 · Cited by 1,106 · cited 1×
“Because double indexing has been shown to improve sample identi-fication using the Illumina platform, 22 we added a second barcode to the P5 adapter.”
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219 · cited 1×
“We previously demonstrated that these sequences can be transferred in vivo(8) and may constitute a potential hazard to patients.(9,10) The level of DNA contamination in final rAAV preparations is thus an important safety concern, particularly if undesirable sequences are packaged in virions and if high-vector doses ar…”
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205 · cited 1×
“Moreover, given the potential presence of a variety of process impurities (chemicals, proteins, and nucleic acid contaminants) in the final AAV vector products, effective methods for the accurate characterization of genetically engineered vectors will be essential.(2,3) During rAAV production in mammalian cells, capsi…”
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189 · cited 1×
“The baculovirus– Sf 9 system has been used for the production of Glybera, an AAV-based product for the treatment of lipoprotein lipase deficiency and the first gene therapy drug approved by the European Medicines Agency (EMA).(15) One of the major concerns noted in the EMA assessment report for Glybera pertained to th…”
Production, purification and characterization of adeno-associated vectors
Ayuso, E., Mingozzi, F., & Bosch, F. (2010) · Current Gene Therapy · doi:10.2174/156652310793797685 · Cited by 151
Self-citationAyuso, E., Blouin, V., Lock, M., McGorray, S., Leon, X., Alvira, M. R., Auricchio, A., Bucher, S., Chtarto, A., Clark, K. R., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.057 · Cited by 94
Self-citationD'Costa, S., Blouin, V., Broucque, F., Penaud-Budloo, M., Fçranois, A., Perez, I. C., Le Bec, C., Moullier, P., Snyder, R. O., & Ayuso, E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.19 · Cited by 89
Self-citationHauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88 · cited 2×
“4–7 We previously demonstrated that these sequences can be transferred in vivo 8 and may constitute a potential hazard to patients.”
Lecomte, E., Tournaire, B., Cogné, B., Dupont, J.-B., Lindenbaum, P., Martin-Fontaine, M., Broucque, F., Robin, C., Hebben, M., Merten, O.-W., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.32 · Cited by 83 · cited 4×
“cells.(11) The present study describes our development of a novel tool for the analysis of DNA impurities originating from the baculovirus–Sf9 production system.”
InfluentialSelf-citationNony, P., Chadeuf, G., Tessier, J., Moullier, P., & Salvetti, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.776-781.2003 · Cited by 51
Self-citationDNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
Schnödt, M., Schmeer, M., Kracher, B., Krüsemann, C., Espinosa, L. E., Grünert, A., Fuchsluger, T., Rischmüller, A., Schleef, M., & Büning, H. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.60 · Cited by 39 · cited 1×
“In mammalian cells, minicircles are used as a strategy to remove prokaryotic sequences from the vector and helper plasmids.(33) To ensure the absence of antibiotic sequences in rAAVs produced in insect cells, the appropriate strategy would be to use BEVs devoid of such sequences.”
Vector characterization methods for quality control testing of recombinant adeno-associated viruses
Wright, J. F., & Zelenaia, O. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-095-9_11 · Cited by 34 · cited 1×
“Because residual DNA contamination is usually measured by qPCR, 26 we compared our SSV-Seq results with those obtained by qPCR determination of the residual baculovirus, rep-cap, and Sf 9 copy numbers.”
Hüser, D., Weger, S., & Heilbronn, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4881-4887.2003 · Cited by 29
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Gimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
“1% of rAAV8 vector genomes content, with an increased proportion for the sequences adjacent to ITRs to be encapsidated, such as the gentamycin-resistance gene in the Bac-to-Bac backbone.(68) Thus, undesirable packaging of vector plasmid sequences is strongly thought to be ITR dependant.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Penaud-Budloo, M., Lecomte, E., Guy-Duché, A., Saleun, S., Roulet, A., Lopez-Roques, C., Tournaire, B., Cogné, B., Léger, A., Blouin, V., Lindenbaum, P., Moullier, P., & Ayuso, E.
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2017-06
- Volume
- 28
- Issue
- 3
- Pages
- 148-162
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W2610880538
- Cited by
- 49
- References
- 14
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.